Robert F. Carey served as executive vice president and chief business officer at Horizon Therapeutics plc from March 2014 until August 2019, during which time Horizon deployed approximately $3.5 billion to acquire or license eight commercial products and three products in development, resulting in Horizon’s enterprise value increasing from approximately $200 million to approximately $6 billion, net sales increasing from $74 million to $1.2 billion and adjusted EBITDA increasing from ($40) million to $450 million. In addition, during Bob’s tenure at Horizon, he assisted in raising in excess of $7 billion in equity and debt capital for Horizon.

Prior to Horizon, Bob was managing director and head of the life sciences investment banking group at JMP Securities International, Inc. from 2003 until 2014 and managing director in the healthcare groups at Dresdner Kleinwort Wasserstein from 2001 until 2003 as well as Vector Securities from 1988 until 2001.

During Bob’s career in investment banking, he assisted biotech and biopharmaceutical companies raise more than $10 billion in initial public offerings, follow-on offerings, debt offerings and private placements as well as served as an advisor on mergers, acquisitions and strategic alliance transactions with a total deal value of more than $10 billion.

Bob also has held roles at Shearson Lehman Hutton and Ernst & Whinney. Bob received his bachelor’s degree from the University of Notre Dame. Bob currently serves on the board of Sangamo Therapeutics, Inc. (SGMO) and Beyond Air, Inc. (XAIR).